Today's Dead Cat Bounce Stock Is Lannett (LCI)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Lannett ( LCI) as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Lannett as such a stock due to the following factors:

  • LCI has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $24.2 million.
  • LCI has traded 218,449 shares today.
  • LCI is up 3.1% today.
  • LCI was down 10% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in LCI with the Ticky from Trade-Ideas. See the FREE profile for LCI NOW at Trade-Ideas

More details on LCI:

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of branded pharmaceutical products in the United States. It offers solid oral, extended release, topical, and oral solution finished dosage forms of drugs that address a range of therapeutic areas. LCI has a PE ratio of 37.1. Currently there are 4 analysts that rate Lannett a buy, no analysts rate it a sell, and 1 rates it a hold.

The average volume for Lannett has been 658,900 shares per day over the past 30 days. Lannett has a market cap of $1.4 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.82 and a short float of 4.4% with 2.87 days to cover. Shares are up 9.9% year-to-date as of the close of trading on Tuesday.

If you liked this article you might like

Lannett Scores FDA OK for Nexium Generic-Biotech Movers

Teva, Mylan Seen to Stay on M&A Sidelines

Teva's Massive Debt Load Just Became an Even Bigger Issue

Teva Shares Are Getting Obliterated Again After Vicious Investment Bank Downgrades

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers